Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Status:
Recruiting
Trial end date:
2024-03-13
Target enrollment:
Participant gender:
Summary
This research is testing whether the investigational drug isatuximab is safe and effective
when used in combination with standard agents for the treatment of newly diagnosed multiple
myeloma.